In what ways did lipitor restructure amino acid linkages?

Lipitor did not restructure amino acid linkages. It is a statin medication developed to lower LDL cholesterol by blocking HMG-CoA reductase, the enzyme responsible for a critical step in cholesterol biosynthesis.

What happens inside cells when Lipitor binds to HMG-CoA reductase?
The drug binds competitively to the enzyme’s active site, displacing the natural substrate HMG-CoA. The binding prevents the conversion of HMG-CoA to mevalonate, reducing the supply of intermediates needed for cholesterol production.

How does a reduction in cholesterol synthesis affect liver cells?
Lowered production inside liver cells triggers upregulation of LDL receptors on the cell surface. These receptors capture circulating LDL particles from the blood and bring them into the cell, thereby lowering serum LDL levels.

Can Lipitor affect other metabolic pathways beyond cholesterol?
Yes. The mevalonate pathway also generates isoprenoids used for protein prenylation, prenylation of Ras-like proteins, and production of ubiquinone. Blocking this pathway may alter these processes, but clinical significance of those changes remains under review.

When does Lipitor’s patent expire?
The original U.S. compound patent covering atorvastatin calcium—the active ingredient in Lipitor—expired in 2011. [1]
https://www.drugpatentwatch.com

Who makes generic versions of Lipitor?
Multiple manufacturers now produce generic atorvastatin, including Ranbaxy, Teva, and Mylan.